Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis.
Joao Pedro FerreiraAna Cristina OliveiraFrancisca A SaraivaFrancisco Vasques-NóvoaAdelino Leite-MoreiraPublished in: European journal of endocrinology (2021)
SGLTi reduces cardiovascular events regardless of insulin use. However, the treatment effect is more homogeneous among insulin-treated patients, supporting the use of SGLTi for the treatment of patients with T2D requiring insulin for glycaemic control.
Keyphrases
- type diabetes
- cardiovascular events
- glycemic control
- cardiovascular disease
- newly diagnosed
- end stage renal disease
- coronary artery disease
- chronic kidney disease
- ejection fraction
- prognostic factors
- metabolic syndrome
- combination therapy
- replacement therapy
- patient reported outcomes
- smoking cessation
- patient reported